

3L

Udruga za skrb djece s posebnim zdravstvenim potrebama 3L

Slavka Batušića 11

10 090 Zagreb

www.3Ludruga.hr

www.facebook.com/SlatkiKaoSecer

www.facebook.com/filmDjecjaposlaKidsstuff

kontakt@slatkikosecer.com

091 5842969

broj upisa kod nadležnog registra 21010120

MB 4015266

OIB 50675579602

IBAN HR 05 2340 0091-110578359, Privredna banka

U Zagrebu,
ožujak 2018. godine

Predmet: Program Informacijom do uspješnog svakodnevnog života s dijabetesom 2017.

IZVJEŠTAJ

kratki opisni izvještaj te financijski izvještaj

Informacijom do uspješnog svakodnevnog života s dijabetesom je volonterski projekt diseminacije stečenih znanja i iskustava. Inicijativu prema 3L za odlazak u San Diego na ADA konferenciju 2017. godine pokrenuli su blogeri portala www.nainzulinu.com (prosinac 2016. godine). Na osnovu inicijative pripremljen je projekt (3L).

Volonteri uključeni u projekt 2017. godine bili su Davor Skeledžija, Ana Špoljarić i Maja Vuković. Volonteri su prikupili namjenska sredstva u direktnom dogovoru s donatorima. Do iznosa namjenski prikupljenih sredstava volonterima su pokriveni troškovi avionskih karata, putnog osiguranja,

smještaja za tri osobe te u preostalom iznosu dnevnice. Od neizravnih troškova 1.000,00 kn uplaćeno je za knjigovodstvo.

Volonteri su prisustvovali konferenciji o šećernoj bolesti Američke dijabetičke asocijacije koja se održala u San Diegu od 9. do 13. lipnja. S preliminarnog programa prethodno je odabrano preko 30 predavanja/tema od interesa 3L, sukladno ciljanim skupinama i obimu dostupnih informacija na konferenciji - okvirno ukupno 10 predavanja/radionica po volonteru.

Volonteri su 3L dostavili zaključno 7 članaka/zaključke sedam predavanja i kratak rezime konferencije koju je prema dogovoru s Davorom Skeleđijom napisao prim. sci. med. dr. Miodrag Đorđević.

Članci su uređeni, lektorirani te objavljeni na stranici 3L. Osvrt na konferenciju objavljen je i u novom broju biltena Zagrebačkog dijabetičkog društva. Navedene članke možete pogledati na našoj stranici

<http://www.3ludruga.hr/informacija/>.

SESSIONS AT-A-GLANCE

Acute and Chronic Complications

- Case-Based Management of NeuroPathHiv
- Hypoglycemic-Associated Autonomic Failure in Diabetes: Revisited
- Physiology of Nervous System Detection of Hypoglycemia
- The Atherogenic Dyslipidemia Complex—New Biomarkers and Therapies Beyond LDL
- Healthy Lifestyle Matters for Patients with Diabetes and Kidney Disease
- Joint ADA/ASN Symposium—Effects of New Diabetic Treatments on Diabetic Kidney Disease
- Urologic Complications and Sexual Dysfunction in Diabetes
- Systemic Correlates of Diabetic Retinopathy
- Diabetes, Drugs, and Heart Failure
- Update on Cardiovascular Outcomes Trials
- Thirty-Year Anniversary of the Foot Care Interest Group—The Diabetic Foot, Then and Now
- 2017 Updates on Charcot Neuroarthropathy

Behavioral Medicine, Clinical Nutrition, Education, and Exercise

- Using Clinic-Based Screening and Intervention to Inform Diabetes Care
- If You Build It, They Will Come—But Will They Stay? Recruitment and Retention in Diabetes Trials
- Cognitive Functioning and Decision-Making in Diabetes
- The New Psychosocial Position Statement from the ADA: Implications for Practice

Clinical Diabetes/Therapeutics

- Continuous Glucose Monitoring: Is Here—Should We Prescribe It for Everyone?—A Pro/Con Discussion
- Overtreatment in Diabetes Management
- Enhancing Diabetes Care in Underserved and Low-Income Populations
- Hypoglycemia Prediction Models for Risk Stratification—Prediction to Prevention
- Novel Risk Factors for Gestational Diabetes Mellitus—Even More to Think About

Effects of Diabetes in Pregnancy on the Developing Brain—Is There a Unifying Mechanism?

- Hyperglycemia and Adverse Pregnancy Outcome Study
- Joint ADA/SPAD Symposium—Current Status of Complications in Women with Type 1 Diabetes—Preserving the Beta Cell Function
- Preventive Diabetes and Associated Comorbidities
- Technology and Automation for Insulin Management
- Combination Therapy in Type 2 Diabetes—Promise Delivered?
- Diabetes: Can We Save the Elderly?
- Into the Endocrine Bowels of Diabetes
- SGLT2 Inhibitors—Still More to Explore
- Joint ADA/JDRF Symposium—Progress towards an Artificial Pancreas
- What's New in Insulin-Related Therapy?
- Pharmacologic Strategies in Diverse Populations
- Harnessing the Power of Digital Connectivity in Sickness and in Health
- Global Therapeutic Challenges and Solutions in Diabetes Care
- Bariatric Surgery in Special Populations
- ADA Diabetes Care Symposium—Diabetes Care and Research through the Ages
- Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results
- Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) International Multicenter Trial
- Joint ADA/AACC Symposium—The Role and Utility of Glycated Proteins—Beyond A1c

ADA Diabetes Symposium—Emerging Therapeutic Targets and Mechanisms of Action

- Effects of Canagliflozin on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus (CANVAS-R) Trial Results
- ADA Pathway to Stop Diabetes Symposium
- Type 1 Diabetes TrialNet Oral Insulin Trial and DIAPREV-IT Trial with GAD-Meritans

Epidemiology/Genetics

- Prediabetes—Are We Missing Opportunities for Intervention and Risk Reduction?
- Healthy—Friend or Bystander in Diabetes Management?
- Successes with Type 1 Diabetes: Complications and Survival
- Obesity and Diabetes—What's the Link, and What Can We Do about It?
- Genome Editing in Islet Biology and Disease
- Gene Expression and Genome Regulation in Islets
- Genetic Evidence for Causal Relationships in Diabetes

Immunology/Transplantation

- Fail—The Islet Microenvironment and Type 1 Diabetes Initiation
- Therapies to Preserve Beta Cells in Type 1 Diabetes
- Can "Omics" and Genome-Wide Association Studies Reveal Therapeutic Links between Type 1 and Type 2 Diabetes?
- Primer on Transplantation for the Clinician
- Technical Innovations in Islet Transplantation—Novel Approaches
- Beta Cells Under Attack—Lessons from Transplantation for New Onset Type 1 Diabetes

Insulin Action/Molecular Metabolism

- Big Data and Generating Novel Hypotheses
- Insulin Action and Cellular Metabolism
- Cellular and Circulating Mediators of Systemic Energy Metabolism
- Immunity and Inflammation as Mediators of Insulin Resistance
- Mechanistic Role of Metabolic Markers in Insulin Action
- Cellular Energy Balance as a Basis for Metabolic Dysregulation
- Mechanistic Links between Cancer, Obesity, and Diabetes
- Cell Signaling in the Central Nervous System as a Mediator of Disease

Integrated Physiology/Obesity

- A Modern Update of Thrifty Genes, Set Points, and Other Models of Obesity
- Novel Metabolites and Mediators of Energy and Metabolic Homeostasis
- System-Based Approaches to Obesity Pathogenesis

Islet Biology/Islet Secretion

- Aging and the Beta Cell
- Beta Cell Maturation
- Chemical Modulation of Beta Cell Function
- Correct Diabetes Therapies Affecting the Islet
- Pancreas Development Revisited from a Human Perspective
- Novel Islet Signaling Pathways
- Islet/Extracellular Matrix Interface
- The Neglected Delta Cell: Secretion Sites are Subject to Change

Factors Influencing Epigenetic Plasticity in the Development of Type 2 Diabetes Mellitus

- The Role of the Intestinal Immune System in Metabolic Disease
- Antidiabetic Actions of Leptin in Insulin-Deficient Animal Models
- The Gut and the Basis of Glucagon Physiology and Neuroendocrinology
- Liver Fat and Metabolic Function—Obesity, Gene, and Gut Interactions
- State of the Science—Molecular Transducers of Lifestyle Interventions to Health Benefits

PRELIMINARY PROGRAM

Submit your research to the Scientific Sessions

- Accepted abstracts are published in the journal *Diabetes*.
- Discuss your research with over 13,000 professional attendees from around the world.
- A limited number of travel grants in the amount of \$1,000 are available to qualified, early-career investigators.

Abstract Submission Deadlines
January 3, 2017

Late Breaking Abstract Submission:
February 1, 2017 - March 13, 2017

Visit scientificsessions.diabetes.org to submit your research today!

6 77th SCIENTIFIC SESSIONS SAN DIEGO, CA | JUNE 9 - 13, 2017 7

Volonteri nisu ispunili obveze u obimu i sukladno postavljenim ciljevima projekta. Očekivani rezultati te ciljevi projekta nisu ostvareni. Suradnja s volonterima u srpnju je raskinuta. Volonteri su preuzeli sve daljnje obveze prema donatorima.

Namjenske donacije:

13.02.2017. namjenska donacija 1.000,00 Adriatic Zagreb Factoring (Davor Skeledžija)

08.03.2017. namjenska donacija 26.850,00 Novo Nordisk (Davor Skeledžija)

24.03.2017. namjenska donacija 7.000,00 Mediligo (Davor Skeledžija)

24.04.2017. namjenska donacija 6.000,00 MediLAB (Davor Skeledžija)

Ukupno namjenske donacije: 40.850,00 kn

Isplaćeno:

15.3.2017. 22.260,00 za troškove avionskih karata (ponuda E-tours, dostavio D. Skeledžija, R1)

20.3.2017. 1.091,00 za troškove osiguranja (ponuda E-tours, dostavio Davor Skeledžija, R1)

7.7.2017. 11.651,93 kn smještaj (povrat Davor Skeledžija, R1*)

7.7.2017. 1.615,68 kn × 3 dnevnice (uplata Davor Skeledžija, Maja Vuković, Ana Špoljarić)

Ukupno isplaćeni troškovi volontiranja: 39.850,00 kn

1.000,00 kn trošak knjigovodstva (neizravni trošak)

* 1.787,43 \$ po osnovi računa R1 od 15.6.2017. za smještaj 7.6. – 14.6.2017., 8 noćenja, plaćeno karticom na ime Davor Skeledžija, R1 račun izdan je za četiri osobe dok su opravdani troškovi za tri osobe te je zbog manjka informacija o stvarnim troškovima iznos smještaja uzet kao ¾ ukupnog iznosa, povrat je u kunama, a tečaj je srednji Hrvatske Narodne banke na dan 7.7. 2017. (6.518822), povrat na tekući račun Davora Skeledžije